Lung Cancer
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
- Details
ClinicalTrials.gov ID:
NCT06627647
Diagnosis Type:
NA
USOR Number:
- Address
,
P: